
The BioPharm Brief: Long-Term Survival Data for a PD-L1/4-1BB Bispecific, Celldex Exits Atopic Dermatitis, and a Fc-Fusion GLP-1 Goes Global
Leads Biolabs details survival data and 2027 ADC combination plans for its PD-L1/4-1BB bispecific opamtistomig, Celldex Therapeutics ends its atopic dermatitis program for anti-KIT antibody barzolvolimab after a phase 2 miss, and Innogen licenses its Fc-fusion GLP-1 receptor agonist efsubaglutide alfa to Arcera Life Sciences for international markets.
Welcome to The BioPharm Brief, your daily snapshot of developments shaping the biopharmaceutical industry. Today: a bispecific aimed at a target that has long been held back by safety problems, a phase 2 miss that clarifies the role of mast cells, and a GLP-1 deal that reaches beyond China.
First,
Next,
And finally,
That’s today’s BioPharm Brief. For analysis and expert insights, please visit BioPharmInternational.com.That’s today’s BioPharm Brief. For analysis and expert insights, please visit BioPharmInternational.com.
Key takeaways
- Engineering around toxicity: Opamtistomig tests whether affinity tuning can make 4-1BB a workable cancer target, though its efficacy data so far are measured against historical rather than randomized controls.
- Mechanism lessons: Celldex’s two discontinuations suggest mast cells aren’t the key driver in itch-dominant skin diseases, but they matter in urticaria.
- Global reach: Chinese GLP-1 developers are licensing their drugs into emerging markets as well as through Western partners.
Related to this article









